New FDA approved cystic fibrosis medicine, Trikafta, among other specialty drugs available through AllianceRx Walgreens Prime

AllianceRx Walgreens Prime

6 January 2020 - Cystic fibrosis patients have access to breakthrough medicine through limited network of specialty pharmacies.

AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies in the U.S., is pleased to include Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), a new breakthrough therapy for cystic fibrosis (CF), among other specialty medications available through its pharmacy.

In addition to Trikafta, the following limited distribution drugs are available through AllianceRx Walgreens Prime:

  • Inrebic (fedratinib) is the first new treatment in nearly a decade for patients living with myelofibrosis, a rare bone marrow cancer. Inrebic is an Impact Biomedicines product (subsidiary of Celgene), which is manufactured for and marketed by Celgene.
  • Nourianz (istradefylline) is used with existing medications (e.g., levodopa and carbidopa) to treat adults with Parkinson's disease who are having "off" episodes. An "off" episode occurs when medications wear off and symptoms return earlier than expected or before the next dose. Nourianz is manufactured by Kyowa Kirin.
  • Nubeqa (darolutamide), manufactured by Bayer HealthCare Pharmaceuticals, is used to treat men with non-metastatic castration-resistant prostate cancer. This is prostate cancer that has not spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. Nubeqa is manufactured by Bayer.
  • Rozlytrek (entrectinib) is used to treat adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have either progressed following treatment or have no satisfactory alternative therapy. It is also used to treat adults whose metastatic non-small cell lung cancer has a specific genetic mutation. Rozlytrek is manufactured by Genentech.

Read AllianceRx Walgreens Prime press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Market access , Pharmacy